Margaret Tooth Sells 2,294 Shares of Trupanion, Inc. (NASDAQ:TRUP) Stock

Trupanion, Inc. (NASDAQ:TRUP) CEO Margaret Tooth sold 2,294 shares of the firm’s stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $31.39, for a total value of $72,008.66. Following the transaction, the chief executive officer now directly owns 118,784 shares of the company’s stock, valued at approximately $3,728,629.76. This trade represents a 1.89 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Trupanion Stock Down 3.6 %

Trupanion stock opened at $32.66 on Friday. The firm has a market cap of $1.38 billion, a price-to-earnings ratio of -142.00, a PEG ratio of 6.02 and a beta of 1.60. The stock has a fifty day simple moving average of $44.46 and a two-hundred day simple moving average of $47.54. Trupanion, Inc. has a 12 month low of $19.69 and a 12 month high of $57.90. The company has a current ratio of 1.71, a quick ratio of 1.66 and a debt-to-equity ratio of 0.39.

Trupanion (NASDAQ:TRUP) last posted its earnings results on Wednesday, February 19th. The financial services provider reported $0.04 EPS for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.02). The business had revenue of $337.31 million during the quarter, compared to the consensus estimate of $335.41 million. Trupanion had a negative return on equity of 3.08% and a negative net margin of 0.75%. Equities analysts predict that Trupanion, Inc. will post 0.13 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on TRUP shares. Stifel Nicolaus reduced their price objective on Trupanion from $44.00 to $41.00 and set a “hold” rating for the company in a research report on Thursday, February 20th. Piper Sandler reduced their target price on Trupanion from $57.00 to $52.00 and set an “overweight” rating for the company in a report on Thursday, February 20th. Two equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $46.60.

Hedge Funds Weigh In On Trupanion

A number of institutional investors and hedge funds have recently modified their holdings of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Trupanion by 14.2% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 89,184 shares of the financial services provider’s stock worth $4,299,000 after buying an additional 11,119 shares during the last quarter. Squarepoint Ops LLC boosted its stake in shares of Trupanion by 32.5% in the 4th quarter. Squarepoint Ops LLC now owns 211,900 shares of the financial services provider’s stock worth $10,214,000 after buying an additional 52,031 shares during the last quarter. State of Wyoming boosted its stake in shares of Trupanion by 111.4% in the 4th quarter. State of Wyoming now owns 11,158 shares of the financial services provider’s stock worth $538,000 after buying an additional 5,880 shares during the last quarter. Sherbrooke Park Advisers LLC purchased a new position in shares of Trupanion in the 4th quarter worth $347,000. Finally, Raiffeisen Bank International AG purchased a new position in shares of Trupanion in the 4th quarter worth $2,505,000.

About Trupanion

Trupanion, Inc, together with its subsidiaries, provides medical insurance for cats and dogs on a monthly subscription basis in the United States, Canada, Continental Europe, and Australia. The company operates in two segments, Subscription Business and Other Business. It serves pet owners and veterinarians.